Lead Product(s) : Obefazimod,Etrasimod
Therapeutic Area : Gastroenterology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Abivax Presents Preclinical Data for UC Therapy with Obefazimod and Etrasimod
Details : Abivax is actively conducting preclinical studies ABX-464 (obefazimod) in combination with Etrasimod for treating Inflammatory Bowel Disease (IBD) in the Mouse Model.
Product Name : ABX464
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 25, 2024
Lead Product(s) : Obefazimod,Etrasimod
Therapeutic Area : Gastroenterology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : INO-02
Therapeutic Area : Gastroenterology
Study Phase : Preclinical
Sponsor : Crohn’s & Colitis Foundation
Deal Size : Undisclosed
Deal Type : Funding
Details : The funding will support the development of INO-02 a new long-acting therapeutic approach to modulate the TREM-1 pathway. TREM-1 is a potential contributor to IBD pathophysiology and targeting this pathway may offer a new treatment for IBD patients with ...
Product Name : INO-02
Product Type : Antibody
Upfront Cash : Undisclosed
September 01, 2023
Lead Product(s) : INO-02
Therapeutic Area : Gastroenterology
Highest Development Status : Preclinical
Sponsor : Crohn’s & Colitis Foundation
Deal Size : Undisclosed
Deal Type : Funding
Lead Product(s) : INO-02
Therapeutic Area : Gastroenterology
Study Phase : Preclinical
Sponsor : Crohn’s & Colitis Foundation
Deal Size : Undisclosed
Deal Type : Funding
Details : The funding will be used to advance Inotrem's inflammatory bowel disease pipeline, including INO-02, a new long-acting therapeutic approach to modulate the TREM-1 pathway.
Product Name : INO-02
Product Type : Antibody
Upfront Cash : Undisclosed
June 11, 2023
Lead Product(s) : INO-02
Therapeutic Area : Gastroenterology
Highest Development Status : Preclinical
Sponsor : Crohn’s & Colitis Foundation
Deal Size : Undisclosed
Deal Type : Funding
Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Study Phase : Preclinical
Sponsor : Takeda Pharmaceutical
Deal Size : $415.0 million
Deal Type : Licensing Agreement
Details : Under the agreement, Takeda will obtain exclusive worldwide rights to develop, manufacture and commercialize Antibody Drug Conjugates (ADC) using a panel of selected antibodies developed by Innate with a primary focus in Celiac disease.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : $5.0 million
March 04, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Highest Development Status : Preclinical
Sponsor : Takeda Pharmaceutical
Deal Size : $415.0 million
Deal Type : Licensing Agreement
Lead Product(s) : EB1010
Therapeutic Area : Gastroenterology
Study Phase : Preclinical
Sponsor : Nestle Health Sciences SA
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Enterome and Nestlé Health Science will co-develop Enterome’s lead EndoMimics™ compound, EB1010, a potent local inducer of IL-10 targeting food allergies and inflammatory bowel disease (IBD). EB1010 is due to enter clinical trials in 2023.
Product Name : EB1010
Product Type : Other Small Molecule
Upfront Cash : $40.7 million
July 18, 2022
Lead Product(s) : EB1010
Therapeutic Area : Gastroenterology
Highest Development Status : Preclinical
Sponsor : Nestle Health Sciences SA
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Study Phase : Preclinical
Sponsor : Crohn’s & Colitis Foundation
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The objective of the R&D collaboration is to confirm the relationship between the activation of the TREM-1 pathway and the severity and progression of IBD in patients, with the ultimate intention of developing a new treatment.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
April 14, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Highest Development Status : Preclinical
Sponsor : Crohn’s & Colitis Foundation
Deal Size : Undisclosed
Deal Type : Collaboration